617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster III

A prospective study reveals feasibility and merits of drug profiling guided precision therapy for children with high risk leukemias

Real world evidence evaluation of the safety and efficacy of intensive chemotherapy with or without gemtuzumab ozogamicin GO in patients with newly diagnosed Acute Myeloid Leukemia AML and favorable or intermediate risk cytogenetics

Subclinical cardiac changes following CPX 351 induction in adults with favorable intermediate risk AML

Real world effectiveness and safety of gilteritinib plus venetoclax and azacitidine in FLT3 mutated acute myeloid leukemia

The venetoclax conundrum Therapeutic drug monitoring of venetoclax Correlation with response in Acute Myeloid Leukemia

Multicenter prospective Phase II study of decitabine priming combined with low dose idarubicin cytarabine and G CSF in children with refractory or relapsed Acute Myeloid Leukemia

Efficacy and safety of CPX 351 in high risk Acute Myeloid Leukemia

Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed AML with CBFB MYH11 or RUNX1 RUNX1T1 fusions Real world outcomes based on international registry data

A comparative analysis of efficacy results in clinical trial publications and US prescribing information demonstrates a high degree of discordance in reported response endpoints for Acute Myeloid Leukemia

Metronomic dose decitabine therapy for TP53 complex karyotype myeloid neoplasms

A Phase II study of azacitidine venetoclax and gilteritinib for newly diagnosed adverse risk FLT3 wild type acute myeloid leukemia

Clinical study reveals the high efficacy and well tolerance of venetoclax combined with homoharringtonine azacitidine and cytarabine in newly diagnosed AML

Rapid bone marrow blast reduction guided selinexor based regimen therapy in relapsed refractory and newly diagnosed acute myeloid leukemia

Survival outcomes with the use of gemtuzumab ozogamycin in patients with acute myeloid leukemia receiving intensive chemotherapy stratified by molecular risk category

Favorable outcomes including post transplant survival are seen independent of baseline skin burden in treatment naïve patients pts with blastic plasmacytoid dendritic cell neoplasm BPDCN treated with tagraxofusp TAG Subgroup analysis of a pivotal Trial

Improved outcomes with higher cumulative doses of cytarabine consolidation in older patients with acute myeloid leukemia

A phase 2 clinical study on intensifying idarubicin dosage for inducing remission in acute myeloid leukemia patients aged 65 and younger

Phase 1 1b dose escalation and expansion of CPX 351 in combination with gemtuzumab ozogamicin in newly diagnosed Acute Myeloid Leukemia AML

Effectiveness and safety of CPX 351 in younger patients

Ruxolitinib combined with dexamethasone is a promising prophylaxis method for differentiation syndrome in acute promyelocytic leukemia APL2022

Olutasidenib monotherapy in patients with mIDH1 Acute Myeloid Leukemia who received prior intensive chemotherapy

VYSION VYxeoS liposomal® Italian Observational study iN the real practice Study design and baseline characteristics